<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00516841</url>
  </required_header>
  <id_info>
    <org_study_id>206OC201</org_study_id>
    <nct_id>NCT00516841</nct_id>
  </id_info>
  <brief_title>A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Facet Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Facet Biotech</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of voloxicimab when administered at 15 mg/kg qwk in subjects with
      platinum-resistant, advanced epithelial ovarian cancer or primary peritoneal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Decision to terminate recruitment based on lack of efficacy
  </why_stopped>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy as measured by objective response rate (ORR). Tumor response based on RECIST criteria.</measure>
    <time_frame>Baseline, and every 8 weeks on study</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Peritoneal Neoplasms</condition>
  <arm_group>
    <arm_group_label>volociximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg/kg volociximab once weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Volociximab</intervention_name>
    <description>15 mg/kg weekly, IV infusions, for 8 weeks or until disease progression or unacceptable toxicity develops</description>
    <arm_group_label>volociximab</arm_group_label>
    <other_name>M200</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must give written informed consent and any authorizations required by local law (e.g.,
             Protected Health Information [PHI]).

          -  Females aged ≥18 years old at the time of informed consent.

          -  Advanced (Stage III or IV), histologically-documented epithelial ovarian cancer or
             primary peritoneal cancer (excluding small, round-cell histologies).

          -  Radiologically-documented evidence of progressive disease.

          -  Platinum-resistant disease defined as having a best response of SD or disease
             progression during or within 6 months of discontinuing a platinum-based chemotherapy
             (carboplatinum, cisplatinum, or another organoplatinum compound).

          -  Progression during or following treatment with topotecan or liposomal doxorubicin.

          -  Three or fewer prior chemotherapy regimens (including a platinum-based therapy).

          -  At least 1 measurable target lesion in accordance with RECIST criteria to assess
             clinical response (tumors within a previously irradiated field are designated as
             non-target).

          -  ECOG Performance Status ≤1.

          -  Life expectancy &gt;12 weeks.

          -  Available paraffin block or unstained paraffin sections on glass slides containing
             representative tumor tissue from the most recent tumor biopsy/resection.

          -  Subjects of child-bearing potential must be willing to practice effective
             contraception during the study and be willing and able to continue contraception for
             at least 6 months after their last dose of study treatment (about 5 half lives).

        Exclusion Criteria:

          -  Screening clinical laboratory values:

               -  Absolute neutrophil count &lt;1500/µL

               -  Platelet count &lt;75,000/µL

               -  Hemoglobin &lt;8.5 g/dL (hemoglobin may be supported by transfusion, erythropoietin,
                  or other approved hematopoietic growth factors; darbopoeitin [Aranesp®] is
                  permitted)

               -  Serum bilirubin &gt;2.0 x upper limit of normal (ULN)

               -  AST and ALT &gt;2.5 x ULN (AST and ALT &gt;5 × ULN for subjects with liver metastasis)

               -  Serum creatinine &gt;2.0 mg/dL

               -  International normalized ratio (INR) &gt;1.5

               -  Activated partial thromboplastin time (aPTT) &gt;1.5 × ULN

          -  Clinically significant peripheral vascular disease.

          -  Non-epithelial ovarian tumors.

          -  Active infection requiring systemic antibiotics, antivirals, or antifungals including
             HIV/AIDS, hepatitis B, or hepatitis C infection.

          -  History of abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal
             abscess within 6 months prior to Day 1.

          -  Serious, non-healing wound, or bone fracture.

          -  Known central nervous system or brain metastases.

          -  History of uncontrolled psychiatric condition within 6 months prior to Day 1.

          -  History of other malignancies within 3 years of Day 1, except for adequately treated
             carcinoma in situ of the cervix, ductal carcinoma in situ (DCIS) of breast, or basal
             or squamous cell skin cancer.

          -  Evidence of autoimmune disease including, but not limited to, ulcerative colitis,
             Crohn's disease, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE)
             sceloderma, or another diseases in which immune function or immune competence is known
             to be impaired.

          -  Any history of lymphoproliferative disorder.

          -  Known human anti-murine antibody (HAMA) and/or human anti-chimeric antibody (HACA).

          -  Any medical condition that may be exacerbated by bleeding, including a known bleeding
             disorder such as a coagulation defect, thrombocytopenia, active gastric or duodenal
             ulcer, or history of GI bleeding.

          -  Significant hemoptysis within one year prior to Study Day 1.

          -  Any investigational, anti-cancer therapy within 6 weeks prior to Day 1.

          -  Any non-investigational, anti-cancer therapy within 4 weeks prior to Day 1.

          -  Prior treatment with anti-angiogenic agents.

          -  Subjects who require treatment with an anti-coagulant with the exception of low-dose
             Aspirin® (≤81 mg/day), warfarin (≤1 mg/day), or heparin for IV catheter patency.

          -  Subjects who are taking concomitant immunomodulatory agents including, but not limited
             to, interferons, interleukins, systemic steroids, cyclosporine, tacrolimus,
             calcineurin inhibitors, chronic low-dose methotrexate, or azathioprine. (The use of
             inhaled or intranasal steroids or oral steroids at a dose of ≤10 mg/day prednisone or
             its equivalent are permitted.)

          -  Active, unstable severe cardiovascular disease, including poorly controlled angina,
             congestive heart failure (CHF), arrhythmias, myocardial infarction (MI),
             cardiomyopathy, atrioventricular (AV) block, electrocardiogram (ECG) evidence of acute
             ischemia, or significant conduction abnormality.

          -  History of thromboembolic or cerebrovascular events, such as stroke, or transient
             ischemic attack (TIA). (Note: Prior history of deep vein thrombosis will not exclude
             subjects from participating in this study.)

          -  Pregnant (positive pregnancy test) or lactating.

          -  Inability to comply with study and follow-up procedures.

          -  Any condition that, in the opinion of the Investigator, makes the subject unsuitable
             for study participation.

          -  Known hypersensitivity to murine or chimeric antibodies.

          -  Major surgery within 4 weeks prior to Day 1.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn Matthews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mary Crowley Medical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Minal Barve, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Oncology PA, Presbyterian</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Burke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Billings Clinic (MCMRC network)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dana Glenn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sharp Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Russell Schilder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nikki Spellman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Gold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oklahoma University Health Science Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Penson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Einstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Holloway, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Hospital Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deborah Armstrong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Kimmel Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Snehel Bhoola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Health University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Winquist, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ernst Lengyel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Glaspy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA JCCC Clinical Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krish Tewari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCI Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C. William Helm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>James Graham Brown Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Glaspy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Sawyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cross Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA JCCC Clinical Research Unit</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCI Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Health University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-1000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic (MCMRC network)</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Health Science Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology PA, Presbyterian</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Center</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>NGA4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2007</study_first_submitted>
  <study_first_submitted_qc>August 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2007</study_first_posted>
  <last_update_submitted>August 21, 2012</last_update_submitted>
  <last_update_submitted_qc>August 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>epithelial ovarian cancer</keyword>
  <keyword>peritoneal cancer</keyword>
  <keyword>platinum-resistant ovarian cancer</keyword>
  <keyword>Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

